William A. Nuerge

WILLIAM A. NUERGE Chief Executive Officer of Xanodyne Pharmaceuticals
has over 25 years pharmaceutical industry experience and is noted for
his high quality project management skills and his ability to identify
talent, to motivate and to lead. Bill began his career with Lafayette
Pharmaceuticals scientist. Over the 16 plus years he served with
Lafayette, Bill held several positions of increasing responsibility
culminating with the position of General Manager and Vice President of
Operations. In 1994, Bill joined Shire US (formerly Richwood
Pharmaceuticals Company, Inc.) as Chief Operating Officer. He was
promoted to President and CEO in 1998. During his tenure as President
and CEO, Shire US exhibited consistent growth and improvement. This
success culminated in 2003 with Shire US showing over $1 billion in
product sales while also achieving over $500 million in operating
profit. These results were a personal milestone for both Bill and the
company. In addition to his contribution towards the outstanding growth
and success of Shire’s US business, Bill has also been a committed
supporter of industry standards and GMP compliance. He led the adoption
by Shire of the PhRMA code guidelines for interactions between health
care professionals and pharmaceutical manufacturers. He also initiated
the development of a Corporate Compliance program for Shire US in
accordance with guidelines established by the Office of the Inspector
General. Bill holds a Bachelor’s of Science degree from Purdue
University. While at Purdue, he also completed two years postgraduate
study in Management and Business Law. In addition, Bill received his MBA
from Indiana Wesleyan University.